Sandoz weighs into European rituximab biosimilar marketSandoz has gained European approval for its biosimilar version of Roche’s blockbuster MabThera/Rituxan (rituximab) to be called Rixathon. The Share XSandoz weighs into European rituximab biosimilar markethttps://pharmaphorum.com/news/sandoz-weighs-european-rituximab-biosimilar-market/